Source:http://linkedlifedata.com/resource/pubmed/id/10090953
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
1999-4-19
|
| pubmed:abstractText |
The idiotype (Id) determinant on the multiple myeloma (MM) protein can be regarded as a tumor-specific marker. Immunotherapy directed at the MM Id may stem the progression of this disease. We report here on the first 12 MM patients treated at our institution with high-dose therapy and peripheral blood stem cell transplantation (PBSCT) followed by Id immunizations. MM patients received PBSCT to eradicate the majority of the disease. PBSCT produced a complete response in 2 patients, a partial response in 9 patients and stable disease in 1 patient. Three to 7 months after high-dose therapy, patients received a series of monthly immunizations that consisted of two intravenous infusions of Id-pulsed autologous dendritic cells (DC) followed by five subcutaneous boosts of Id/keyhole limpet hemocyanin (KLH) administered with adjuvant. Between 1 and 11 x 10(6) DC were obtained by leukapheresis in all patients even after PBSCT. The administration of Id-pulsed DC and Id/KLH vaccines were well tolerated with patients experiencing only minor and transient side effects. Two of 12 patients developed an Id-specific, cellular proliferative immune response and one of three patients studied developed a transient but Id-specific cytotoxic T-cell (CTL) response. Eleven of the 12 patients generated strong KLH-specific cellular proliferative immune responses showing the patients' immunocompetence at the time of vaccination. The two patients who developed a cellular Id-specific immune response remain in complete remission. Of the 12 treated patients, 9 are currently alive after autologous transplantation with a minimum follow-up of 16 months, 2 patients died because of recurrent MM and 1 patient succumbed to acute leukemia. These studies show that patients make strong anti-KLH responses despite recent high-dose therapy and that DC-based Id vaccination is feasible after PBSCT and can induce Id-specific T-cell responses. Further vaccine development is necessary to increase the proportion of patients that make Id-specific immune responses. The clinical benefits of Id vaccination in MM remain to be determined.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Cancer Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Dexamethasone,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Hemocyanin,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin Idiotypes,
http://linkedlifedata.com/resource/pubmed/chemical/Melphalan,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine,
http://linkedlifedata.com/resource/pubmed/chemical/keyhole-limpet hemocyanin
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0006-4971
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
93
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2411-9
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:10090953-Adjuvants, Immunologic,
pubmed-meshheading:10090953-Adult,
pubmed-meshheading:10090953-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10090953-Cancer Vaccines,
pubmed-meshheading:10090953-Combined Modality Therapy,
pubmed-meshheading:10090953-Cyclophosphamide,
pubmed-meshheading:10090953-Dendritic Cells,
pubmed-meshheading:10090953-Dexamethasone,
pubmed-meshheading:10090953-Doxorubicin,
pubmed-meshheading:10090953-Feasibility Studies,
pubmed-meshheading:10090953-Female,
pubmed-meshheading:10090953-Follow-Up Studies,
pubmed-meshheading:10090953-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:10090953-Hemocyanin,
pubmed-meshheading:10090953-Humans,
pubmed-meshheading:10090953-Immunocompetence,
pubmed-meshheading:10090953-Immunoglobulin Idiotypes,
pubmed-meshheading:10090953-Immunotherapy, Active,
pubmed-meshheading:10090953-Lymphocyte Activation,
pubmed-meshheading:10090953-Male,
pubmed-meshheading:10090953-Melphalan,
pubmed-meshheading:10090953-Middle Aged,
pubmed-meshheading:10090953-Multiple Myeloma,
pubmed-meshheading:10090953-Prednisone,
pubmed-meshheading:10090953-Recurrence,
pubmed-meshheading:10090953-Remission Induction,
pubmed-meshheading:10090953-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:10090953-Transplantation, Autologous,
pubmed-meshheading:10090953-Treatment Outcome,
pubmed-meshheading:10090953-Tumor Markers, Biological,
pubmed-meshheading:10090953-Vaccination,
pubmed-meshheading:10090953-Vincristine
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.
|
| pubmed:affiliation |
Division of Oncology, Stanford Blood Center, Stanford University Medical Center, Stanford, CA, USA.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|